tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
Company AnnouncementsSarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
6d ago
SRPT
Unusually active option classes on open August 7th
PremiumThe Fly
Unusually active option classes on open August 7th
26d ago
CCJ
PCG
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
PremiumCompany Announcements
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
27d ago
SRPT
Sarepta price target lowered to $35 from $37 at Oppenheimer
PremiumThe Fly
Sarepta price target lowered to $35 from $37 at Oppenheimer
27d ago
SRPT
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
PremiumRatings
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
27d ago
SRPT
Gil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
PremiumRatingsGil Blum Reiterates Sell on Sarepta as 2026 Guidance Trimmed and Regulatory Uncertainty Weighs on Growth Outlook
27d ago
SRPT
Sarepta reports Q2 adjusted EPS 64c, consensus 49c
Premium
The Fly
Sarepta reports Q2 adjusted EPS 64c, consensus 49c
28d ago
SRPT
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Sarepta Therapeutics Inc. (SRPT) Q2 Earnings Cheat Sheet
1M ago
SRPT
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
PremiumThe Fly
Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts
1M ago
SRPT
Sarepta Therapeutics Appoints Michael Severino as CEO
PremiumCompany Announcements
Sarepta Therapeutics Appoints Michael Severino as CEO
1M ago
8K
SRPT
Sarepta appoints Severino as Chief Executive Officer
PremiumThe Fly
Sarepta appoints Severino as Chief Executive Officer
1M ago
SRPT
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
PremiumRatings
Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13
1M ago
SRPT
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
PremiumThe FlyCiti sees intensifying competition for Sarepta from Dyne Therapeutics
1M ago
DYN
SRPT
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
Premium
The Fly
Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
2M ago
AMT
CNK
Sarepta price target lowered to $20 from $23 at Piper Sandler
Premium
The Fly
Sarepta price target lowered to $20 from $23 at Piper Sandler
2M ago
SRPT
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
2M ago
SRPT
H.C. Wainwright says Sarepta news does not signal full approvals
PremiumThe Fly
H.C. Wainwright says Sarepta news does not signal full approvals
2M ago
SRPT
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
PremiumThe Fly
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
2M ago
SRPT
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
PremiumCompany Announcements
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
3M ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe FlyActing FDA head vows to block political interference, Endpoint News says
3M ago
AZN
BMY
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
Premium
Company Announcements
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
3M ago
SRPT
FDA issues draft guidance to help accelerated cell, gene therapies for patients
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
3M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >